Skip to content
10-Q

Quarterly Report

TG THERAPEUTICS, INC. TGTX

0001437749-26-015246

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 153.08M sh
Shares Diluted Q1 2026 · Mar 31, 2026 160.06M sh
Shares Diluted Q1 2026 · Mar 31, 2025 162.77M sh
Capex Q1 2026 · Mar 31, 2026 $51K
Capex Q1 2026 · Mar 31, 2025 $25K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$17.89M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$28.72M
Long Term Debt Q1 2026 · Mar 31, 2026 $745.14M
Long Term Debt Q1 2026 · Dec 31, 2025 $245.65M
Short Term Investments Q1 2026 · Mar 31, 2026 $72.22M
Short Term Investments Q1 2026 · Dec 31, 2025 $62.82M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $442.21M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $79.15M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $132.14M
Stockholders Equity Q1 2026 · Mar 31, 2026 $583.13M
Stockholders Equity Q1 2026 · Dec 31, 2025 $648.02M
Stockholders Equity Q1 2026 · Mar 31, 2025 $237.29M
Stockholders Equity Q1 2026 · Dec 31, 2024 $222.36M
Current Liabilities Q1 2026 · Mar 31, 2026 $187.11M
Current Liabilities Q1 2026 · Dec 31, 2025 $153.76M
Total Liabilities Q1 2026 · Mar 31, 2026 $945.71M
Total Liabilities Q1 2026 · Dec 31, 2025 $415.23M
Current Assets Q1 2026 · Mar 31, 2026 $1.09B
Current Assets Q1 2026 · Dec 31, 2025 $630.76M
Total Assets Q1 2026 · Mar 31, 2026 $1.53B
Total Assets Q1 2026 · Dec 31, 2025 $1.06B
Eps Diluted Q1 2026 · Mar 31, 2026 $0.12
Eps Diluted Q1 2026 · Mar 31, 2025 $0.03
Eps Basic Q1 2026 · Mar 31, 2026 $0.14
Eps Basic Q1 2026 · Mar 31, 2025 $0.03
Sga Expense Q1 2026 · Mar 31, 2026 $88.22M
Sga Expense Q1 2026 · Mar 31, 2025 $50.33M
Rd Expense Q1 2026 · Mar 31, 2026 $48.4M
Rd Expense Q1 2026 · Mar 31, 2025 $46.36M
Net Income Q1 2026 · Mar 31, 2026 $19.78M
Net Income Q1 2026 · Mar 31, 2025 $5.06M
Operating Income Q1 2026 · Mar 31, 2026 $34.8M
Operating Income Q1 2026 · Mar 31, 2025 $8.62M
Revenue Q1 2026 · Mar 31, 2026 $204.92M
Revenue Q1 2026 · Mar 31, 2025 $120.86M